BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Employees - 16,
CEO - Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.,
Sector - Healthcare,
Country - CA,
Market Cap - 18.36M
Altman ZScore(max is 10): -23.01, Piotroski Score(max is 10): 1, Working Capital: $1931735, Total Assets: $9363567, Retained Earnings: $-97537292, EBIT: -30795709, Total Liabilities: $6136676, Revenue: $0
AryaFin Target Price - $0.03 - Current Price $4.95 - Analyst Target Price $128.50
| Ticker | BCTX |
| Index | - |
| Curent Price | 4.95 |
| Change | -17.91% |
| Market Cap | 18.36M |
| Average Volume | 1.36M |
| Income | -11.59M |
| Sales | 0.00M |
| Book Value/Share | 1.22 |
| Cash/Share | 1.35 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 18 |
| Moving Avg 20days | 16.22% |
| Moving Avg 50days | 20.08% |
| Moving Avg 200days | -43.65% |
| Shares Outstanding | 3.71M |
| Earnings Date | Mar 12 BMO |
| Inst. Ownership | 12.23% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 4.05 |
| Price/Cash | 3.67 |
| Price/FCF | - |
| Quick Ratio | 1.37 |
| Current Ratio | 1.37 |
| Debt/Equity | 0.00 |
| Return on Assets | -107.36% |
| Return on Equity | -490.69% |
| Return on Investment | -321.74% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 55.47 |
| BETA(β) | 1.23 |
| From 52week Low | 65.00% |
| From 52week High | -86.48% |
| EPS | -5.00 |
| EPS next Year | -1.77 |
| EPS next Qtr | -1.76 |
| EPS this Year | -16.33% |
| EPS next 5 Year | 31.60% |
| EPS past 5 Year | 47.85% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 58.25% |
| Sales Y/Y | - |
| EPS Q/Q | 78.02% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | -20.10% |
| ATR(14) | 0.91 |
| Perf Week | 15.38% |
| Perf Month | 23.44% |
| Perf Quarter | -16.86% |
| Perf Year | -85.78% |
| Perf YTD | -41.59% |
| Target Price | 128.50 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer